drugset / Trial / NCT00064402

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

NCT00064402

Phase 3 Completed 741 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the bronchodilator effect and safety of multiple daily doses of arformoterol administered for 12 weeks as maintenance treatment in patients with COPD

Timeline

Start
2002-04
Primary completion
2004-03
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Arformoterol Small molecule 15 ug Inhaled
Subject Arformoterol Small molecule 25 ug Inhaled
Subject Arformoterol Small molecule 50 ug Inhaled
Comparator Salmeterol Other / unclassified 42 ug Inhaled